This clinical trial is focused on studying the effects of a treatment for Idiopathic Pulmonary Fibrosis (IPF), a lung disease that causes scarring of the lungs, making it difficult to breathe. The treatment being tested is called Axatilimab, which is given as a solution through an intravenous infusion, meaning it is administered directly into the bloodstream. The study will compare the effects of Axatilimab to a placebo to understand its impact on lung function over a period of 26 weeks.
The purpose of the study is to evaluate how Axatilimab affects lung function in people with IPF. Participants will be randomly assigned to receive either Axatilimab or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The study will last for 26 weeks, during which participants will have regular check-ups to monitor their lung function and overall health.
Throughout the study, researchers will measure the rate of decline in lung capacity, which is how much air the lungs can hold, and observe any changes in symptoms or disease progression. The study aims to provide valuable information on the safety and effectiveness of Axatilimab as a potential treatment for IPF, helping to improve the quality of life for those affected by this condition.
Belgium 
Czechia 
France 
Germany 
Italy 
Poland 
Romania 
Spain 
